Clinical Trial

Reducing Breathlessness With Dronabinol in COPD Patients

Study acronym: BONG
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-06-18; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2025-03-24
Trial Details
NCT Number NCT06473701
Lead Sponsor Vejle Hospital
Collaborators: Region of Southern Denmark, Odense Patient Data Explorative Network, University of Southern Denmark, University of Aarhus
Conditions COPD, Breathlessness, Cannabis
Enrollment 30 participants
Start Date 2025-02-26
Primary Completion 2026-09 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-17